Why Is Arcutis Biotherapeutics Stock Surging Thursday?
Cantor Fitzgerald initiated Arcutis (ARQT) at Overweight with a $48 target, citing Zoryve's potential for $3.5B in peak sales.
Stocks · News reference
Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment
The FDA approved Atebrioz by Mirum Pharmaceuticals and Incyte to treat FOP in patients aged 12 and older, reducing abnormal bone formation.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Truist Securities Maintains Hold on Incyte, Raises Price Target to $115
Truist Securities analyst Srikripa Devarakonda maintains Incyte (NASDAQ:INCY) with a Hold and raises the price target from $105 to $115.
HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $152 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $152 price target.
RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $114
RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $109 to $114.
Stifel Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $156
Evercore ISI Group Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $146
Evercore ISI Group analyst Gavin Clark-Gartner maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $135 to $146.